Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note released on Friday morning. The brokerage issued a sell rating on the stock.

Several other equities research analysts also recently issued reports on CANF. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Stock Up 0.6 %

Shares of NYSE CANF opened at $1.58 on Friday. The company’s fifty day simple moving average is $1.79 and its 200 day simple moving average is $2.31. The firm has a market cap of $5.59 million, a PE ratio of -0.88 and a beta of 1.36. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the period. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.